Barriers to the treatment of hepatitis C: Patient, provider, and system factors

Journal of General Internal Medicine

Volumn 20, Issue 8, 2005, Pages 754-758

  Morrill, James A ^a   Shrestha, Melissa ^b   Grant, Richard W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MGH Revere HealthCare Center   (United States)

Author keywords

Barriers to treatment; Hepatitis C virus infection; Interferon and ribavirin therapy; Substance abuse

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH CARE SYSTEM; HEALTH CENTER; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL DISEASE; PATIENT REFERRAL; PREVALENCE; PRIMARY MEDICAL CARE; VIREMIA;

ADULT; COHORT STUDIES; COMMUNITY HEALTH CENTERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; MALE; MASSACHUSETTS; MENTAL DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; URBAN POPULATION;

EID: 23744484452     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2005.0161.x     Document Type: Article

References (26)

1. Alter M, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62.
2. Flamm S. Chronic hepatitis c virus infection. JAMA. 2003;289: 2413.
3. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
4. Lauer G, Walker B. Medical progress: hepatitis c virus infection. N Engl J Med. 2001;345:41.
5. Manns MP. et al. Peginterferon-alpha2b plus ribavirin compared with interferon-alpha2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;348:958-65.
6. Cawthorne CH, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97:149-55.
7. Falck-Ytter Y. et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288-92.
8. Yawn BP, et al. Identification and management of hepatitis C patients in primary care clinics. J Fam Pract. 2002;51:135-40.
9. Allen SA, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-90.
10. Backmund M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-93.
11. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Dependence. 2002;67:117-23.
12. Thiel DHV. et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165-8.
13. Anonymous. Management of hepatitis c: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
14. Librero J, Peiro S, Ordinana R. Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. J Clin Epidemiol. 1999;52:171-9.
15. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the US preventive services task force. Ann Intern Med. 2004;140:465-79.
16. USPSTF. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140:462-4.
17. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345:215-7.
18. Schiff E. The alcoholic patient with hepatitis C virus infection. Am J Med. 1999;107:953-93.
19. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Dependence. 2001;61:211-5.
20. Bamberger JD, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90:699-701.
21. Smirnoff M, et al. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis. 1998;2:134-9.
22. Anonymous. Management of hepatitis C. NIH Consens Statements. 1997;15:1-41.
23. Edlin BR, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211-4.
24. McGinn T. How primary care enhances hepatitis C treatment (conference workshop). J Gen Intern Med. 2004;19:11.
25. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:3226-36.
26. Grant RW, et al. Impact of population management with direct physician feedback on care of patients with type 2 diabetes. Diabetes Care. 2003; 26:2275-80.